Tyzeka (Telbivudine) is approved for the treatment of chronic hepatitis B virus infection (HBV) in adult patients with evidence of viral complication and either persistent elevations in serum aminotranferases or histologically active disease.
Tyzeka (Telbivudine) is made by Novartis Pharma and distributed by Idenix Pharmaceuticals, Inc.
Tyzeka is also known as Sebivo in Canada and in other countries.